We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit
News

Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit

Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit
News

Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Regenetech Inc., the adult stem cell company which uses NASA-licensed technology, announces that at the Second Annual Stem Cell Summit, it makes its licenses available to stem cell banks for its cellXpansion™ technology, which expands hematopoietic stem cells for autologous use.
 
Dr. David Bonner, Chief Executive Officer of Regenetech, said: “We believe that the essential barrier to wide-spread medical use of adult stem cells is the lack of convenient and economical therapeutic doses of adult stem cells.  We believe that Regenetech’s technology provides the most cost-effective solution to this problem.  Through the use of our cellXpansion™ system, we hope to make adult stem cell therapy available on a widespread basis.”
 
In order to encourage broader use of its technology, Regenetech will also make available research licenses at nominal cost to not-for-profit institutions pursuing stem cell research.
 
Under license from NASA, Regenetech has extended NASA’s patented human progenitor cell technology for use in stem cell banking based on peripheral or umbilical cord blood sources of stem cells.
Advertisement